Therapy of primary CNS lymphoma with methotrexate-based chemotherapy and deferred radiotherapy: Preliminary results
Therapy of primary CNS lymphoma with methotrexate-based chemotherapy and deferred radiotherapy: Preliminary results
复制标题
DOI：
10.1212/wnl.46.6.1757
复制
发表时间：
1996-06-01
期刊：
影响因子：
9.9
通讯作者：
Hochberg, FH
中科院分区：
文献类型：
--
作者：
Cher, L;Glass, J;Hochberg, FH
原发性中枢神经系统淋巴瘤的无病生存率随着以甲氨蝶呤为基础的放疗前化疗的出现而提高。在我们之前的两个系列中，8名拒绝放射治疗的患者中有6名出现反应持续时间延长。我们已经治疗了另外11例患者的甲氨蝶呤为基础的化疗，没有后续计划的辐射。有些人接受维持化疗。大多数有持久的反应，很少或没有毒性。延长的反应可以在没有放射治疗的情况下维持，从而避免潜在的长期放射毒性。
Disease-fi ee survival in primary CNS lymphoma has im proved with the advent of methotrexate-based pre-irradiation chemotherapy. Prolonged response durations have been noted in six of eight patients refusing radiation therapy in two of our prior series. We have treated an additional 11 patients with methotrexate-based chemotherapy without subsequent planned irradiation. Some received maintenance chemotherapy. Most have had durable responses with little or no toxicity. Prolonged responses can be maintained without radiation therapy, thus avoiding potential long-term radiation toxicity.